Molecular Basis of Loss Aversion

NCT06034158 | Unknown

• 1 other identifier: 20230496
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to test the roles of dopamine and norepinephrine in decision making related to loss aversion in the healthy population. The main question it aims to answer is whether temporarily boosting dopamine activity or temporarily suppressing norepinephrine activity has an impact on processing of potential gains and losses in financial decision making, social decision making, transaction decision making and moral decision making. Accordingly, participants will complete four decision-making tasks, namely investment task, driving task, trading task, and die task, after taking madopar, propranolol or placebo. Participants' psychological traits and psychiatric symptoms will be assessed once they are enrolled before the first-session day.

Conditions

Healthy

Outcome Measures

Primary Outcomes (7)

• Choices to invest or not in the investment task

  Participants decide whether or not to accept investment options that entail a 50/50 chance of winning some amount of money and losing some amount of money.

  between 1-2 hours after taking the drugs or the placebo

• Response times to invest or not in the investment task

  Participants decide whether or not to accept investment options that entail a 50/50 chance of winning some amount of money and losing some amount of money.

  between 1-2 hours after taking the drugs or the placebo

• Choices to turn or not in the driving task

  Participants decide whether or not to make turns during driving in order to sacrifice some number of person(s) to save some number of person(s) .

  between 1-2 hours after taking the drugs or the placebo

• Response times to turn or not in the driving task

  Participants decide whether or not to make turns during driving in order to sacrifice some number of person(s) to save some number of person(s) .

  between 1-2 hours after taking the drugs or the placebo

• Choices to buy or sell in the trading task

  Participants decide whether or not to buy or sell a product at certain prices.

  between 1-2 hours after taking the drugs or the placebo

• Response times to buy or sell in the trading task

  Participants decide whether or not to buy or sell a product at certain prices.

  between 1-2 hours after taking the drugs or the placebo

• Reported outcomes in die task

  Participants report the outcome for each throw of the die.

  between 1-2 hours after taking the drugs or the placebo

Secondary Outcomes (1)

• Affects

  before and 1 hour after taking the drugs or the placebo

Study Arms (6)

madopar-propranolol-placebo

OTHER

In a within-subjects design, participants will take madopar, propranolol, and placebo each once in three separate sessions.

Drug: single-dose madopar, single-dose propranolol, and single-dose placebo by order

madopar-placebo-propranolol

OTHER

In a within-subjects design, participants will take madopar, placebo, and propranolol each once in three separate sessions.

Drug: single-dose madopar, single-dose placebo, and single-dose propranolol by order

propranolol-madopar-placebo

OTHER

In a within-subjects design, participants will take propranolol, madopar, and placebo each once in three separate sessions.

Drug: single-dose propranolol, single-dose madopar, and single-dose placebo by order

propranolol-placebo-madopar

OTHER

In a within-subjects design, participants will take propranolol, placebo, and madopar each once in three separate sessions.

Drug: single-dose propranolol, single-dose placebo, and single-dose madopar by order

placebo-propranolol-madopar

OTHER

In a within-subjects design, participants will take placebo, propranolol, and madopar each once in three separate sessions.

Drug: single-dose placebo, single-dose propranolol, and single-dose madopar by order

placebo-madopar-propranolol

OTHER

In a within-subjects design, participants will take placebo, madopar, and propranolol each once in three separate sessions.

Drug: single-dose placebo, single-dose madopar, and single-dose propranolol by order

Interventions

single-dose madopar, single-dose propranolol, and single-dose placebo by order DRUG

Participants will take madopar, propranolol, and placebo (orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.

madopar-propranolol-placebo

single-dose madopar, single-dose placebo, and single-dose propranolol by order DRUG

Participants will take madopar, placebo(orange juice), and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.

madopar-placebo-propranolol

single-dose propranolol, single-dose madopar, and single-dose placebo by order DRUG

Participants will take propranolol, madopar, and placebo(orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.

propranolol-madopar-placebo

single-dose propranolol, single-dose placebo, and single-dose madopar by order DRUG

Participants will take propranolol, placebo(orange juice), and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.

propranolol-placebo-madopar

single-dose placebo, single-dose propranolol, and single-dose madopar by order DRUG

Participants will take placebo(orange juice), propranolol, and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.

placebo-propranolol-madopar

single-dose placebo, single-dose madopar, and single-dose propranolol by order DRUG

Participants will take placebo(orange juice), madopar, and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.

placebo-madopar-propranolol

Eligibility Criteria

• Age: 25 Years - 40 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Age 25-40 years old (including boundary value).
• Elementary school education or above, able to understand the research content.
• Body temperature, blood pressure, heart rate, respiratory rate, and electrocardiogram are all normal. Among them, the blood pressure range is 100-139/70-89 mmHg, and the heart rate range is 60-85 beats/min.

You may not qualify if:

• Vulnerable groups, including people with mental illness, cognitive impairment, critically ill subjects, minors, pregnant women, illiterates, etc.
• Family history of genetic diseases.
• Major physical diseases, including cardiovascular, respiratory, digestive, renal, endocrine, blood and other systemic diseases.
• History of alcohol/drug dependence.
• Lactating women.
• The cardiopulmonary function test results are poor.
• Have ever taken madopar or propranolol for medical use.

Sponsors & Collaborators

• Sir Run Run Shaw Hospital: lead

Study Sites (1)

Sir Run Run Shaw Hospital

Hangzhou, Zhejiang, 360000, China

RECRUITING

Related Publications (1)

• Sheng F, Ramakrishnan A, Seok D, Zhao WJ, Thelaus S, Cen P, Platt ML. Decomposing loss aversion from gaze allocation and pupil dilation. Proc Natl Acad Sci U S A. 2020 May 26;117(21):11356-11363. doi: 10.1073/pnas.1919670117. Epub 2020 May 8.

  PMID: 32385152 BACKGROUND

MeSH Terms

Interventions

benserazide, levodopa drug combination; Propranolol

Intervention Hierarchy (Ancestors)

Phenoxypropanolamines; Propanolamines; Amino Alcohols; Alcohols; Organic Chemicals; Propanols; Amines; Naphthalenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Polycyclic Compounds

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Deputy Chief Physician

Study Record Dates

• First Submitted: September 5, 2023
• First Posted: September 13, 2023
• Study Start: September 18, 2023
• Primary Completion: March 1, 2024
• Study Completion: September 1, 2024
• Last Updated: September 26, 2023

Record last verified: 2023-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)